drugset / Trial / NCT03776721

Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting

NCT03776721

Phase 2 Completed 80 enrolled Odense University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Currently, lymphedema is primarily addressed conservatively with compression garments. Regenerative medicine may provide a new treatment option for lymphedema. This Phase 3 trial will examine the efficacy, effectiveness and safety of freshly isolated adipose-derived stromal cells administered in conjunction with a fat grafting procedure to the affected axillary region.

Timeline

Start
2018-12-18
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject adipose-derived regenerative cells Cell therapy 4 ml Other

Indications